MedTrace Logo

Digital Diabetes Remission Trial

NCT05647226 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-09-17

No results posted yet for this study

Summary

This is a multicentre, open-label Randomised Controlled Trial run in the United Kingdom. The main aims are to assess whether the Habitual Remission Programme (digital therapeutics + 12-week 800kcal/day low-energy diet, delivered remotely) is more likely to lead to weight loss and remission in adults with type 2 diabetes, when compared to standard of care.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

COMBINATION_PRODUCT

Digital therapeutic and intensive lifestyle programme

Initial 12-week LED and behaviour education app.

OTHER

Standard of care

Standard of care.

Sponsors & Collaborators

  • Lindus Health

    collaborator INDUSTRY

  • Habitual Health Ltd

    lead INDUSTRY

Principal Investigators

  • Carol Le Roux, Professor · Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-09
Primary Completion
2024-07-30
Completion
2024-07-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05647226 on ClinicalTrials.gov